TY - JOUR
T1 - Global and regional burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria in 2019: A systematic analysis from the MICROBE database
AU - Zha, Lei
AU - Li, Shirong
AU - Guo, Jun
AU - Hu, Yixin
AU - Pan, Lingling
AU - Wang, Hanli
AU - Zhou, Yun
AU - Xu, Qiancheng
AU - Lu, Zhiwei
AU - Kong, Xiang
AU - Tong, Xinzhao
AU - Cheng, Yusheng
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2024/12/24
Y1 - 2024/12/24
N2 - Objectives: To quantify the global and regional burden of bloodstream infections associated with and attributable to carbapenem-resistant Gram-negative bacteria. Methods: We extracted data from the Measuring Infectious Causes and Resistance Outcomes for Burden Estimation database, which includes the estimated burden of 23 pathogens and 88 pathogen-drug combinations across 12 major infectious syndromes globally in 2019. The number and rate of deaths, as well as disability-adjusted life-years linked to bloodstream infections, were systematically analyzed. Results: In 2019, bloodstream infections accounted for approximately 2.91 (95% UI, 1.74-4.53) million deaths globally, with Gram-negative bacteria responsible for 51.1% of these fatalities. An estimated 391,800 (95% UI 221,500-631,400) deaths were associated with carbapenem resistance, constituting 26.3% of all bloodstream infection-related deaths. The highest burden of carbapenem resistance was seen in South Asia, East Asia, and Eastern Europe, while the lowest burden was in Sub-Saharan Africa. Notably, Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the leading carbapenem-resistant pathogens contributing to mortality. Conclusions: Our findings underscore the significant global burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria, with notable regional disparities. There is an urgent need for enhanced surveillance, improved infection prevention and control measures, and better access to first-line antibiotics, particularly in high-burden regions.
AB - Objectives: To quantify the global and regional burden of bloodstream infections associated with and attributable to carbapenem-resistant Gram-negative bacteria. Methods: We extracted data from the Measuring Infectious Causes and Resistance Outcomes for Burden Estimation database, which includes the estimated burden of 23 pathogens and 88 pathogen-drug combinations across 12 major infectious syndromes globally in 2019. The number and rate of deaths, as well as disability-adjusted life-years linked to bloodstream infections, were systematically analyzed. Results: In 2019, bloodstream infections accounted for approximately 2.91 (95% UI, 1.74-4.53) million deaths globally, with Gram-negative bacteria responsible for 51.1% of these fatalities. An estimated 391,800 (95% UI 221,500-631,400) deaths were associated with carbapenem resistance, constituting 26.3% of all bloodstream infection-related deaths. The highest burden of carbapenem resistance was seen in South Asia, East Asia, and Eastern Europe, while the lowest burden was in Sub-Saharan Africa. Notably, Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the leading carbapenem-resistant pathogens contributing to mortality. Conclusions: Our findings underscore the significant global burden of bloodstream infections caused by carbapenem-resistant Gram-negative bacteria, with notable regional disparities. There is an urgent need for enhanced surveillance, improved infection prevention and control measures, and better access to first-line antibiotics, particularly in high-burden regions.
KW - Antimicrobial resistance
KW - Bacteremia
KW - Bloodstream infection
KW - Carbapenem resistance
KW - Disease burden
KW - Gram-negative bacteria
UR - http://www.scopus.com/inward/record.url?scp=85214473631&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2024.107769
DO - 10.1016/j.ijid.2024.107769
M3 - Article
C2 - 39725209
AN - SCOPUS:85214473631
SN - 1201-9712
VL - 153
SP - 1
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
M1 - 107769
ER -